SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.
Jun ZhaoXinmin YuDingzhi HuangZhiyong MaBo GaoJiuwei CuiQian ChuQing ZhouMeili SunDaphne DayJingxun WuHongming PanLifeng WangMark VoskoboynikZhehai WangYunpeng LiuHui LiJuan ZhangYanyan PengYi-Long WuPublished in: Journal for immunotherapy of cancer (2023)
NCT03666143.